The proportion of subjects undergoing DLT events in each dose cohorts during the DLT observation period;Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0

The proportion of subjects undergoing DLT events in each dose cohorts during the DLT observation period;Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0